Drugs that contain Sumatriptan Succinate
1. Alsuma patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7811254 | MERIDIAN MEDCL | Autoinjector with needle depth adapter |
Aug, 2027
(3 years from now) | |
Market Authorisation Date: 29 June, 2010
Treatment: Acute treatment of migraine attacks, with or without aura, and the treatment of cluster headache episodes
Dosage: INJECTABLE;SUBCUTANEOUS
ALSUMA family patents
2. Onzetra Xsail patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6715485 | CURRAX | Nasal delivery device |
Mar, 2020
(4 years ago) | |
| US8555877 | CURRAX | Nasal delivery device |
Mar, 2020
(4 years ago) | |
| US8047202 | CURRAX | Nasal devices |
Jul, 2023
(9 months ago) | |
| US8327844 | CURRAX | Nasal delivery method |
Oct, 2023
(6 months ago) | |
| US9119932 | CURRAX | Nasal delivery device |
Apr, 2024
(3 days from now) | |
| US7975690 | CURRAX | Nasal devices |
Aug, 2025
(1 year, 3 months from now) | |
| US9108015 | CURRAX | Nasal delivery devices |
Sep, 2025
(1 year, 4 months from now) | |
| US8590530 | CURRAX | Nasal delivery devices |
Sep, 2025
(1 year, 4 months from now) | |
| US11571531 | CURRAX | Powder delivery devices |
Feb, 2026
(1 year, 10 months from now) | |
| US10124132 | CURRAX | Nasal delivery |
Mar, 2027
(2 years from now) | |
| US10398859 | CURRAX | Nasal delivery devices |
Dec, 2027
(3 years from now) | |
| US8875704 | CURRAX | Nasal administration |
Apr, 2028
(3 years from now) | |
| US10722667 | CURRAX | Nasal administration |
Dec, 2028
(4 years from now) | |
| US10076615 | CURRAX | Nasal delivery |
Jul, 2029
(5 years from now) | |
| US8550073 | CURRAX | Nasal delivery |
Oct, 2029
(5 years from now) | |
| US8899229 | CURRAX | Powder delivery devices |
Aug, 2030
(6 years from now) | |
| US9649456 | CURRAX | Nasal administration |
Oct, 2030
(6 years from now) | |
| US8978647 | CURRAX | Nasal delivery |
Dec, 2030
(6 years from now) | |
| US10478574 | CURRAX | Nasal administration |
Nov, 2033
(9 years from now) | |
| US10076614 | CURRAX | Nasal delivery devices |
Oct, 2034
(10 years from now) | |
Market Authorisation Date: 27 January, 2016
Treatment: Method of drug delivery via the nasal cavity; Treatment of migraine via delivery of sumatriptan via the nasal cavity; Method of delivering sumatriptan to a nasal cavity; Acute treatment of migraine by...
Dosage: POWDER;NASAL
ONZETRA XSAIL family patents
3. Sumavel Dosepro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5891086 | ENDO VENTURES LTD | Needle-less injector |
Jul, 2014
(9 years ago) | |
| US6681810 | ENDO VENTURES LTD | Filling device for a needleless injector cartridge |
Dec, 2015
(8 years ago) | |
| US6174304 | ENDO VENTURES LTD | Filling device for a needless injector cartridge |
Dec, 2015
(8 years ago) | |
| US5957886 | ENDO VENTURES LTD | Spring-Powered dispensing device |
Mar, 2016
(8 years ago) | |
| US6251091 | ENDO VENTURES LTD | Needleless injector drug capsule and filling method |
Dec, 2016
(7 years ago) | |
| US6135979 | ENDO VENTURES LTD | Spring-powered dispensing device for medical purposes |
Mar, 2017
(7 years ago) | |
| US6280410 | ENDO VENTURES LTD | Method of filling a drug capsule and article produced thereby |
Mar, 2017
(7 years ago) | |
| US8343130 | ENDO VENTURES LTD | Needleless injector |
Oct, 2022
(1 year, 6 months ago) | |
| US8241244 | ENDO VENTURES LTD | Needleless injector drug capsule and a method for filling thereof |
Nov, 2022
(1 year, 4 months ago) | |
| US8491524 | ENDO VENTURES LTD | Needleless injector drug capsule and a method for filling thereof |
Nov, 2022
(1 year, 4 months ago) | |
| US8267903 | ENDO VENTURES LTD | Casing |
Mar, 2023
(1 year, 1 month ago) | |
| US8241243 | ENDO VENTURES LTD | Needleless injector drug capsule and a method for filling thereof |
Aug, 2023
(8 months ago) | |
| US8118771 | ENDO VENTURES LTD | Needleless injector drug capsule and a method for filling thereof |
Aug, 2023
(8 months ago) | |
| US8287489 | ENDO VENTURES LTD | Device for readying a needle free injector for delivery |
Dec, 2024
(7 months from now) | |
| US7901385 | ENDO VENTURES LTD | Casing |
Jul, 2026
(2 years from now) | |
| US7776007 | ENDO VENTURES LTD | Device for readying a needle free injector for delivery |
Nov, 2026
(2 years from now) | |
Market Authorisation Date: 26 November, 2013
Treatment: NA
Dosage: INJECTABLE;SUBCUTANEOUS
SUMAVEL DOSEPRO family patents
4. Zecuity patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6745071 | TEVA BRANDED PHARM | Iontophoretic drug delivery system |
Feb, 2023
(1 year, 1 month ago) | |
| US8155737 | TEVA BRANDED PHARM | Pharmacokinetics of iontophoretic sumatriptan administration |
Apr, 2027
(2 years from now) | |
| US9427578 | TEVA BRANDED PHARM | Pharmacokinetics of iontophoretic sumatriptan administration |
Apr, 2027
(2 years from now) | |
| US7973058 | TEVA BRANDED PHARM | Transdermal methods and systems for the delivery of anti-migraine compounds |
Apr, 2027
(2 years from now) | |
| US8470853 | TEVA BRANDED PHARM | Transdermal methods and systems for the delivery of anti-migraine compounds |
Apr, 2027
(2 years from now) | |
| US8597272 | TEVA BRANDED PHARM | Pharmacokinetics of iontophoretic sumatriptan administration |
Apr, 2027
(2 years from now) | |
| US9272137 | TEVA BRANDED PHARM | Transdermal methods and systems for the delivery of anti-migraine compounds |
Sep, 2027
(3 years from now) | |
| US8366600 | TEVA BRANDED PHARM | Polyamine enhanced formulations for triptan compound iontophoresis |
Apr, 2029
(5 years from now) | |
| US8983594 | TEVA BRANDED PHARM | Electronic control of drug delivery system |
Nov, 2030
(6 years from now) | |
| US9327114 | TEVA BRANDED PHARM | User-activated self-contained co-packaged iontophoretic drug delivery system |
Oct, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jan 17, 2016 |
Market Authorisation Date: 17 January, 2013
Treatment: Method for treating acute migraine in adults, with or without aura, comprising iontophoretic transdermal delivery of sumatriptan or a salt thereof; Method for treating acute migraine in adults, with ...
Dosage: SYSTEM;IONTOPHORESIS
ZECUITY family patents
5. Zembrace Symtouch patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10537554 | TONIX MEDS | Pharmaceutical composition for treating migraine |
Jan, 2036
(11 years from now) | |
| US11364224 | TONIX MEDS | Pharmaceutical composition for treating migraine |
Jan, 2036
(11 years from now) | |
Market Authorisation Date: 28 January, 2016
Treatment: Treatment of migraine
Dosage: SOLUTION;SUBCUTANEOUS
ZEMBRACE SYMTOUCH family patents